Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-EPO maintenance therapy in renal anemia
NCT05629598Phase 2Unknown
- Sponsor
- China Resources Angde Biopharmaceutical
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anemia of chronic kidney disease (5 arms), sponsored by China Resources Angde Biopharmaceutical. Primary endpoints: Change of mean hemoglobin compared to baseline during fixed treatment and Change of mean hemoglobin during dose adjustment period. Status: unknown.
02
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT05629598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629598.